Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $47.67 Average PT from Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Three ...
MML Investors Services LLC Purchases New Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
MML Investors Services LLC bought a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & ...